Halozyme Therapeutics in (halo 0.25 03/01/27)

13F holders, Q1 2026 (March 31)
14holders
3new positions
2sold out
$1.04avg. 13F price*

At the end of Q1 2026, 14 institutions reported holding Halozyme Therapeutics in (halo 0.25 03/01/27) in their 13F filings, unchanged from Q4 2025. 3 opened new positions and 2 sold out. The largest holders were TPG GP A, LLC ($10.4M), Balyasny Asset Management L.P. ($6.5M) and Focus Partners Wealth ($3.9M).

Company
Halozyme Therapeutics in (halo 0.25 03/01/27)
CUSIP
40637HAD1
Latest filing quarter
Q2 2026

History

Number of 13F holders

05101520 Q1 2024: 10Q1 2024Q2 2024: 11Q2 2024Q3 2024: 16Q3 2024Q4 2024: 15Q4 2024Q1 2025: 17Q1 2025Q2 2025: 15Q2 2025Q3 2025: 17Q3 2025Q4 2025: 14Q4 2025Q1 2026: 14Q1 2026Q2 2026: 11Q2 2026

Total Exit/New Position Q4 2025 → Q1 2026

InstitutionsTotal Value
New Positions3$18.2M
Exits2$8K

All 13F filers, Q4 2025 → Q1 2026: 18,030,000 shares bought and 42,976 shares sold, net +17,987,024 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 14 holders

TPG GP A, LLC 0.30% New 10,000,000 $10.4M
Balyasny Asset Management L.P. 0.01% New 6,200,000 $6.5M
Focus Partners Wealth 0.00% Reduce -0.8% 3,751,000 $3.9M
Rational Advisors, Inc. 0.34% Add +21.7% 2,970,000 $3.1M
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 0.00% No change 2,650,000 $2.7M
Ssi Investment Management LLC 0.11% New 1,300,000 $1.3M
Oppenheimer Asset Management Inc. 0.00% Reduce -2.9% 170,000 $176K
&partners 0.00% Reduce -0.8% 130,000 $135K
Mariner, LLC 0.00% No change 59,000 $61K
Stephens Inc. 0.00% No change 53,000 $55K
Commonwealth Equity Services, LLC 0.00% No change 20,000 $21K
MML Investors Services, LLC 0.00% No change 18,000 $19K
MAI Capital Management 0.00% No change 15,000 $15K
Cetera Investment Advisers 0.00% No change 12,000 $12K

"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 0.25 03/01/27)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 0.25 03/01/27) the manager owns.